Network Meta-analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects From Induction and Bias of the Results
Authors:
Open Access
- 1 October 2021
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 19 (10) , 2219-2221
Abstract
No abstract availableFunding Information
- Janssen Research and Development
This publication has 8 references indexed in Scilit:
- AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative ColitisGastroenterology, 2020
- Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysisCurrent Medical Research and Opinion, 2020
- First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-AnalysisClinical Gastroenterology and Hepatology, 2020
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2019
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative ColitisNew England Journal of Medicine, 2019
- Treatment sequence network meta-analysis in Crohn’s disease: a methodological case studyCurrent Medical Research and Opinion, 2019
- Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor AntagonistsClinical Gastroenterology and Hepatology, 2017
- Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 YearClinical and Translational Gastroenterology, 2016